Wave Life Sciences, Inc.

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

WVE$3.48+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets

(In thousands, except share amounts)

	March 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$243,075	$302,078
Accounts receivable	—	1,422
Prepaid expenses	8,062	9,544
Other current assets	6,839	7,350
Total current assets	257,976	320,394
Long-term assets:
Property and equipment, net of accumulated depreciation of $47,027 and $46,329 as of March 31, 2025 and December 31, 2024, respectively	9,566	10,128
Operating lease right-of-use assets	16,581	17,870
Restricted cash	3,772	3,760
Other assets	448	55
Total long-term assets	30,367	31,813
Total assets	$288,343	$352,207
Liabilities, Series A preferred shares, and shareholders’ equity
Current liabilities:
Accounts payable	$14,358	$16,262
Accrued expenses and other current liabilities	7,813	21,081
Current portion of deferred revenue	57,312	65,972
Current portion of operating lease liability	7,884	7,638
Total current liabilities	87,367	110,953
Long-term liabilities:
Deferred revenue, net of current portion	5,584	6,099
Operating lease liability, net of current portion	15,715	17,766
Total long-term liabilities	21,299	23,865
Total liabilities	$108,666	$134,818
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at March 31, 2025 and December 31, 2024	$7,874	$7,874
Shareholders’ equity:
Ordinary shares, no par value; 154,093,313 and 153,037,286 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	$1,179,336	$1,175,181
Additional paid-in capital	161,407	156,454
Accumulated other comprehensive loss	(204)	(262)
Accumulated deficit	(1,168,736)	(1,121,858)
Total shareholders’ equity	$171,803	$209,515
Total liabilities, Series A preferred shares, and shareholders’ equity	$288,343	$352,207

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.